(Q42770955)

English

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.

scientific article published on 29 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hyun Cheol Chung

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

9

object named as

Jae Kyung Roh

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Kyung Soo Park

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Yoon Jung Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Yong Sang Hong

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Tae Won Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hye Ryun Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Dal-Hyun Kim

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Chin Kim

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

29 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

672-680

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21188464%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

https://scigraph.springernature.com/pub.10.1007/s10637-010-9625-x

0 references

Evolving treatment of advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Carbamate analogues of fumagillin as potent, targeted inhibitors of methionine aminopeptidase-2.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Antiangiogenesis agents in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Clinical pharmacokinetics of capecitabine

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9625-X

21 January 2018

AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21188464

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of oxaliplatin: a critical review

1 reference

https://pubmed.ncbi.nlm.nih.gov/21188464

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/21188464

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21188464

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types

1 reference

https://pubmed.ncbi.nlm.nih.gov/21188464

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21188464

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42770955&oldid=2144574812"